Psychedelics & Cannabis

IV DMT psychedelic SPL026 reduces major depression in phase 2a.

Phase 3 trial shows COMP360 psilocybin rapidly reduces treatment-resistant depression symptoms with durable effects and good safety, as Compass moves toward FDA review.

New research highlights psilocybin's potential in treating treatment-resistant OCD, while cannabinoids show little evidence of efficacy.

Psychedelic therapy shows promise for treating PTSD, with recent studies indicating safety and efficacy.

Explore the potential of LSD as a groundbreaking treatment for anxiety and depression.

Incannex Healthcare's PSX-001 shows promise in treating generalized anxiety disorder, offering innovative, effective solutions beyond traditional therapies.

Learn more about the transformative potential of psychedelics in treating depression and mood disorders through expert insights and groundbreaking research.

Psyence BioMed phase 2b trial explores psilocybin therapy for adjustment disorder in palliative care, aiming for groundbreaking treatment advancements.

Recent trials reveal LSD's potential to significantly reduce anxiety symptoms in GAD, offering a promising alternative to traditional treatments.

Rick Doblin discusses FDA's recent feedback on MDMA-assisted therapy for PTSD, emphasizing transparency and the therapy's potential in clinical practice.

Cannabis use among older adults surges as they seek relief from pain and anxiety, prompting clinicians to navigate complex treatment challenges.

Incannex Healthcare shared positive data from its phase 2 clinical trial of PSX-001, a psilocybin-assisted psychotherapy treatment for generalized anxiety disorder.

PharmaTher's KETARx gains FDA approval, paving the way for innovative ketamine treatments in pain management and mental health disorders.

Ketamine-assisted psychotherapy has transformative potential as a groundbreaking approach to mental health that enhances healing through psychedelic experiences.

New research reveals ketamine's safe use for treating eating disorders, offering hope for patients with comorbid treatment-resistant depression.

New clinical trial results reveal BPL-003's rapid and durable antidepressant effects, paving the way for innovative treatments in treatment-resistant depression.

Compass Pathways reports significant progress in psilocybin research, showing promise for treatment-resistant depression in a pivotal phase 3 trial.

Ketamine-assisted psychotherapy: enhancing healing through emotional support and insight-driven therapy for depression.

What should you know about the lesser known psychedelics? Clinical insights from Jacob Perlson, MD, MPH, at the APA Annual Meeting.

Combination therapy of TMS and ketamine could enhance brain perfusion and neuroplasticity.

The first patient has been dosed in MindMed’s phase 3 Emerge study evaluating the efficacy of MM120 ODT.

A single dose of psilocybin was associated with a significant and sustained reduction in depressive symptoms and possible improvement of PTSD and burnout experienced by clinicians from the front line of the COVID-19 pandemic.

Dennis S. Charney, MD, discussed the importance of trying and risking failure when studying new potential treatments, as well as the future of treating depression.

Dennis S. Charney, MD, celebrates the 40th anniversary of Psychiatric Times discussing the history of psychiatry and where he hopes the future lies.